NEU

3.15%

$21.27 neuren pharmaceuticals limited

Success in Phase 1 Alzheimer's trial adds $40 bn, page-5

First 5 Last

Share
Profile

Follow
mjc159

1,531 Posts.

151

23/03/15

15:58

Post #: 14963172
Share

Originally posted by hottod ↑

If nothing else, the Biogen story shows that the market loves therapies with successful trials in neurological conditions where there is a large market with unmet need.

Alzheimer’s is perhaps the most obvious condition in this category as it taps into the aging Baby Boomer market. There are estimated to be more than 5 million Americans with Alzheimer’s, with the annual incidence in the US estimated to be approximately 470,000.

But there are also other neurological conditions with large markets of unmet need.

Traumatic brain injury is one. In the United States the estimated annual incidence of TBI (a condition with no current treatment) is 1.7 million. Neuren’s Phase 2 results of NNZ-2566 in both mild and moderate to severe TBI should be known by later this year. With Neuren’s current shareprice at .10, the market doesn’t seem to be anticipating trial success. But what if the trials do demonstrate efficacy? What if the drug demonstrates not only efficacy, but also a better safety profile than Biogen’s drug?

It’s also worth remembering Neuren’s second drug, NNZ-2591, which is currently being prepared for IND submission. It has already demonstrated efficacy in pre-clinical models of stroke. The estimated annual incidence of stroke in the US is 800,000 – higher than Alzheimer’s. Finally, it shouldn't be forgotten that the patent for NNZ-2591, issued last year with respect to “improvement of cognitive performance in impaired animals”, also makes claim for treatment of Alzheimer’s Disease, Dementia, Parkinson’s Disease and age-related memory loss (along with other conditions).

Expand

Thanks hottod

Do you have any numbers on the incidence of age-related memory loss. From personal experience, it starts to kick-in around 40.
"Where did I put my car keys again?"

NEU Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

There are more pages in this discussion • 2 more messages in this thread...

First 5 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $21.27		Change 0.650(3.15%)		Mkt cap ! $2.718B

Open	High	Low	Value	Volume
$20.84	$21.56	$20.76	$7.760M	364.5K

Buyers (Bids)

No.	Vol.	Price($)
2	1378	$21.24

Sellers (Offers)

Price($)	Vol.	No.
$21.29	218	1

View Market Depth

No.	Vol.	Price($)
1	200	21.240
3	2798	21.230
2	1055	21.210
2	9379	21.200
1	1805	21.180

Price($)	Vol.	No.
21.300	12763	1
21.350	30	1
21.380	471	1
21.400	700	1
21.410	25	1

Last trade - 16.10pm 28/06/2024 (20 minute delay)

NEU (ASX) Chart

Success in Phase 1 Alzheimer's trial adds $40 bn, page-5

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Success in Phase 1 Alzheimer's trial adds $40 bn, page-5

Top Stories

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Ava Risk Group expands US presence with A$0.7M Substation Deal

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News